eBulletin Newsletter

NCCN Flash Update: NCCN Guidelines Updated for Hepatocellular Carcinoma and Biliary Tract Cancers

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Hepatocellular Carcinoma. These NCCN Guidelines® are currently available as Version 4.2024.

Link directly to the Updates section of the NCCN Guidelines: Hepatocellular Carcinoma

HCC-I (1 of 2)

  • Footnote l added: Nivolumab and hyaluronidase-nvhy is not approved for concurrent use with IV ipilimumab; however, for nivolumab monotherapy, nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.
  • Footnote p added: Nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.

 

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Biliary Tract Cancers. These NCCN Guidelines are currently available as Version 6.2024.

Link directly to the Updates section of the NCCN Guidelines: Biliary Tract Cancers

BIL-C (2 of 5)

  • Footnote i added: Nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.

MS-1

  • The discussion was updated to reflect the changes in the algorithm.

 

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Biliary Tract Cancers to reflect the currently published NCCN Guidelines for Biliary Tract Cancers v6.2024.

  • The following NEW template has been published:
    •  BIL38Zanidatamab-hrii

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.